Q3 2025 Paysign Inc Earnings Call Transcript
Key Points
- PaySign Inc (PAYS) reported record revenue of $21.6 million for Q3 2025, marking a 41.6% increase year-over-year.
- Adjusted EBITDA reached a record $5 million, up 78% from the previous year, indicating strong operational performance.
- The Patient Affordability business saw exceptional growth, with revenue increasing by 142% to $7.9 million.
- The company expanded its support capacity with a new 30,000 square foot patient support center, enhancing service delivery.
- PaySign Inc (PAYS) is actively expanding into the retail pharmaceutical space, which presents significant growth opportunities.
- The plasma industry is facing an oversupply issue, which is expected to normalize only in the first half of 2026.
- Revenue per plasma center declined due to the immaturity of new centers and the oversupply of plasma.
- Despite growth, the company faces challenges in maintaining consistent revenue per program due to seasonal fluctuations.
- The approval of the Blood Establishment Computer System (BECS) by the FDA has been delayed, impacting potential new revenue streams.
- The company is experiencing increased operating expenses, including a 20.3% rise in compensation and benefits.
Good afternoon. My name is Shamali, and I will be your conference operator today. At this time, I would like to welcome everyone to the Paysign, Inc. third quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
The comments on today's call regarding Paysign's financial results will be on a GAAP basis unless otherwise noted. Paysign's earnings release was disseminated to the SEC earlier today and can be found on the Investor Relations section of our website, paysign.com, which includes reconciliations of non-GAAP measures to GAAP reported amounts.
Additionally, as set forth in more detail in the earnings release, I would like to remind everyone that today's call will include forward-looking statements regarding Paysign's future performance. Actual performance could differ materially from these forward-looking statements. Information about the factors that could affect future performance is summarized at the end of Paysign's earnings release in its recent SEC filings.
Lastly, a replay of this call will be available
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
